Startseite>>Signaling Pathways>> GPCR/G protein>> LPL Receptor>>SLF1081851

SLF1081851

Katalog-Nr.GC66459

SLF1081851 ist ein Spns2-Inhibitor, hemmt die S1P-Freisetzung (IC50=1,93 μM). SLF1081851 spielt eine SchlÜsselrolle in der Entwicklung und im Immunsystem.

Products are for research use only. Not for human use. We do not sell to patients.

SLF1081851 Chemische Struktur

Cas No.: 2763730-97-6

Größe Preis Lagerbestand Menge
5mg
135,00 $
Auf Lager
10mg
216,00 $
Auf Lager
25mg
459,00 $
Auf Lager
50mg
765,00 $
Auf Lager
100mg
1.215,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system[1][2].

Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule, and Spns2 exerts the functions to maintain lymph S1P[1].
SLF1081851 (compound 16d) (0-5 μM; 18-20 h) inhibits S1P release with an IC50 value of 1.93 μM in Hela cells[1].
SLF1081851 (0-30 μM; 20 min) inhibits mSphK1 (recombinant mouse SphK) (10 μM) and mSphK2 (5 μM) in a dose-dependent manner and suggests at least 15-fold selectivity (SphK1 IC50≥30 μM; SphK2 IC50≈30 μM)[1].

SLF1081851 (20 mg/kg; i.p., 4 h postdose) significantly inhibits circulating lymphocytes and plasma S1P, and recapitulates the genetic phenotype of Spns2 null mice[1].

Animal Model: C57BL/6 mice[1]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection; blood was drawn 4 h postdose
Result: Significantly decreased circulating lymphocyte count and plasma S1P concentration.
Animal Model: SpragueDawley mice (4-week-old)[1]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose
Result: Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).

Bewertungen

Review for SLF1081851

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SLF1081851

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.